New hope for ROS1-Positive lung cancer: JYP0322 takes on chemo
NCT ID NCT07154368
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial compares a new drug called JYP0322 with standard platinum-based chemotherapy in 207 people with advanced ROS1-positive non-small cell lung cancer who have already been treated with ROS1-targeted therapy. The main goal is to see if JYP0322 delays cancer growth better than chemotherapy. Patients on chemotherapy can switch to JYP0322 if their cancer worsens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JYP0322
- What this could lead to
- If successful, JYP0322 could offer a new treatment option for people with ROS1-positive lung cancer whose disease has progressed after initial targeted therapy.
- What could go wrong
- This is an early-stage Phase 3 trial with only 207 participants, so results may not apply to everyone. The drug may not improve survival or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?